Intensive research into the molecular causes of cancer has led to the development of a range of innovative and targeted therapies which are used to selectively inactivate the molecular mechanisms responsible for tumour progression and the growth of cancer cells. These therapies can inhibit the proliferation of cancer cells and induce programmed cell death (apoptosis). They are not effective in all cancer patients due to the genetic heterogeneity of tumours. Personalised oncology aims to establish a direct link between tumour cell genotypes and sensitivity to bioactive substances, so that the patient first and foremost receives the targeted therapy with the maximum clinical benefit.
In the project an experimental approach is being developed to complement diagnostic biomarker studies. We plan to develop organotypic cancer models that enable the direct testing of the clinical efficacy of cancer therapies in cell and tissue cultures (in vitro). A large number of potential cancer therapies, which are often combinations of targeted drugs and conventional chemotherapeutic agents, could
be quickly tested for their clinical efficacy on a personalised Basis.
The project is funded by Niederösterreichische Forschungs- und Bildungsges.m.b.H. (NFB).